Updated:
JIC Huawen Investment
JIC Huawen Investment was established in 2013 as the primary direct-investment vehicle of China Jianyin Investment Ltd., the sprawling state-owned...
JIC Huawen Investment
JIC Huawen Investment was established in 2013 as the primary direct-investment vehicle of China Jianyin Investment Ltd., the sprawling state-owned investment conglomerate commonly known as JIC. CEO Cao Qun has run the platform since inception, initially under founding chairman Du Pengfei. Unlike JIC's broader portfolio — which spans trust, securities, and holding-company functions — Huawen was purpose-built to take concentrated equity stakes in private and growth-stage companies that align with Beijing's industrial modernization agenda. The firm invests across four declared verticals: advanced manufacturing, medical health, energy development, and national security, with a later overlay on consumption upgrading. Its deal flow is a mix of direct equity and fund commitments. The most transparent example of its cross-border appetite is the 2018 acquisition of Nature's Care Biotech, an Australian nutraceutical manufacturer, executed through a co-investment structure with Tamar Alliance Partners Fund I — a vehicle backed by CITIC Pacific. Domestically, Huawen has anchored investments in China's media sector, notably partnering with Hunan Broadcasting and Television in Mango TV and Mango Media, illustrating a dual mandate that services both strategic state interests and commercial media growth. Geographic activity spans mainland China and select overseas markets, with Australia the most visible non-domestic theater. The platform's scale remains opaque — no public AUM or aggregate-deployment figure exists — and headcount is not disclosed. In May 2024, JIC Huawen was absorbed into a broader state-capital restructuring: China Jianyin Investment was merged into China Investment Corporation, placing Huawen's portfolio under the sovereign wealth fund's umbrella and likely altering its governance and capital-allocation chain, an event confirmed by CIC's official announcement. Beyond pureplay investing, the firm operates a wholly distinct commercial subsidiary, JIC Bookstore Cultural Spaces, with physical locations in Beijing, Shanghai, and Hangzhou — a cultural-retail asset that sits alongside, not inside, the investment portfolio and serves as an unusual brand extension for a state investment vehicle. Structurally, JIC Huawen is a state-capital allocator that behaves like a direct private equity firm — writing equity checks, taking board positions, and partnering with commercial co-investors — but answers to a wholly different set of stakeholders. Its parent merger into CIC makes it one of few pureplay direct-investment arms inside a sovereign wealth fund, a hybrid architecture where commercial returns, supply-chain security, and state broadcasting assets coexist under a single reporting line. That tension — between financial discipline and state mandate — defines the firm's structural differentiator more than any single deal or strategy note.
General information
Firm type
Generalist
Year founded
2013
AUM
Undisclosed
Location
Region
Asia
Country
China
City
Beijing
Corporate office
Beijing, China
Principals
Cao Qun
Chief Executive Officer
Du Pengfei
Former Chairman
Sector focus
Frequently asked questions
How does JIC Huawen Investment fit into China Jianyin Investment's broader structure?
JIC Huawen functions as the dedicated direct-equity investment platform within the JIC group, which also operates trust, securities, and other financial services units. Huawen takes concentrated minority or control positions in private companies, as opposed to the liquid-markets or holding-company functions elsewhere in JIC. As of mid-2024, the entire JIC group was merged into China Investment Corporation, moving Huawen under the sovereign wealth fund's governance (per CIC, May 2024).
What investment sectors does JIC Huawen target?
The firm's declared mandate covers four domains: advanced manufacturing, medical health, energy development, and national security. In practice, its portfolio also extends into consumption upgrading — the Nature's Care Biotech acquisition is the clearest example — and media, through its partnership with Hunan Broadcasting. There is no publicly stated negative list of excluded sectors.
What is JIC Huawen's relationship with CITIC and Tamar Alliance?
Tamar Alliance Partners Fund I, a vehicle under CITIC Pacific, served as the co-investor alongside JIC Huawen in the 2018 acquisition of Australian vitamin company Nature's Care Biotech. This partnership demonstrates Huawen's willingness to syndicate deals with other state-affiliated capital pools when pursuing cross-border consumer-health assets. The exact ownership split in the Nature's Care deal has not been publicly disclosed.
Who makes investment decisions at JIC Huawen Investment?
CEO Cao Qun has led the firm's investment operations since its founding in 2013. The prior chairman, Du Pengfei, provided initial strategic oversight. Decision-making authority sits with Huawen's internal investment committee, though ultimate capital allocation traces back through the parent entity — now China Investment Corporation following the 2024 merger — and carries an implicit alignment requirement with state industrial policy.
Does JIC Huawen operate any assets outside of its investment portfolio?
Yes. JIC Bookstore Cultural Spaces is a wholly owned commercial subsidiary that operates brick-and-mortar bookstores in Beijing, Shanghai, and Hangzhou. These retail spaces sit adjacent to — not inside — the investment portfolio and represent an unusual brand-extension strategy for a state investment firm. No public information suggests the bookstore operations are structured as part of the investment fund economics.
How does the 2024 merger into China Investment Corporation affect JIC Huawen?
The merger transfers JIC Huawen's ultimate governance from China Jianyin Investment to CIC, China's sovereign wealth fund. This places Huawen's direct-investment portfolio inside a $1T+ institution with its own direct-deal teams and global asset allocation framework. The operational impact on deal autonomy, staffing, and strategy has not been publicly detailed as of the merger announcement in May 2024.
Is JIC Huawen Investment's AUM publicly available?
No. JIC Huawen does not publicly disclose assets under management, aggregate deployment figures, or fund-level commitment sizes. The parent group's balance sheet is the primary capital source, and individual deal values — beyond the estimated size of the Nature's Care acquisition — are not reported. Any third-party AUM figure for this platform would be an estimate.
Profile maintained by Altss using OSINT (open-source intelligence), regulatory filings, licensed data partners, and verified direct submissions. Read the methodology. Last updated: . Continuous refresh with full update cycles at least every 30 days.
Need institutional-grade insight on asset managers?
Altss delivers:
Prefer a guided tour?
We’ll walk you through: